Three babies, all between two and five months old, landed in the hospital after consuming the same organic powdered infant formula sold at Target stores nationwide. On Saturday, Nara Organics pulled the product from shelves in a voluntary recall, and federal health officials told parents to stop using it immediately.
The infants fell ill in April and May in California, Pennsylvania, and Washington, the FDA said. Each had consumed Nara Organics Whole Milk Organic Powdered infant formula before developing infant botulism, a rare but dangerous condition in which bacteria produce a toxin inside a baby's gut.
The recall covers all lots of the powdered formula sold through Target brick-and-mortar locations, Target.com, and Nara.com. The formula is manufactured in Europe but sold exclusively in the United States, a detail the CDC confirmed as it urged caregivers to act without delay.
The CDC's instructions are blunt. Anyone with the formula should stop feeding it to their child today. The agency told caregivers to label opened cans "DO NOT USE" and store them safely away from any other baby-feeding items for at least a month, in case investigators need to test remaining product.
"Label it 'DO NOT USE' and keep it stored in a safe place away from other items you feed your baby for at least a month. If no symptoms appear after a month, throw the leftover formula away."
That guidance, from the CDC, also asks parents who have opened a can to photograph it and record the lot number and use-by date. Infant botulism can affect any baby under one year old, and the agency wants families watching for symptoms even if their child currently appears healthy.
The three hospitalized infants survived after receiving BabyBIG antitoxin, the FDA-approved treatment for infant botulism, the New York Post reported. That outlet also identified the specific lot numbers consumed by the sick babies: 709125280E14F2, 709125288E14F2, and 708125174E14F2. Whether any of the three children remained hospitalized at the time of the recall has not been disclosed.
Here is a detail that raises as many questions as it answers: no tested lots of the formula have come back positive for Clostridium botulinum, the bacterium responsible for the toxin. The New York Post noted that Nara Organics recalled all whole-milk powdered infant formula lots anyway, working alongside federal and state health officials to determine the cause.
The FDA framed the move as one taken out of "an abundance of caution" and called botulism "a serious threat to the health of infants." That language suggests regulators do not yet have a definitive contamination finding, but they were unwilling to leave product on shelves while the investigation continues.
For parents, that gap between the clinical cases and the lab results is unsettling. Three babies got sick. All three consumed the same brand. The bacteria hasn't been confirmed in the product itself. The investigation is ongoing.
The 2022 Abbott infant formula crisis, triggered by contamination at a Michigan plant, left store shelves bare for months and sent parents scrambling across state lines. Any formula recall now inevitably prompts the question: will this create another shortage?
The FDA moved quickly to head off that fear. The agency said Nara Organics Whole Milk Organic Infant Formula accounts for less than one percent of all infant formula sold in the United States, AP News reported. The outbreak, regulators said, does not create broader supply concerns for parents and caregivers.
That one-percent figure matters. It means the vast majority of families using formula will not be affected by the recall at all. But for the parents who chose Nara Organics, often drawn by the "organic" label and the European manufacturing pedigree, the disruption is immediate and personal.
The formula's European origin adds another layer. American parents have increasingly turned to European-manufactured baby formulas in recent years, sometimes importing them directly, sometimes buying brands that have secured U.S. distribution. Nara Organics followed the latter path, landing shelf space at one of the country's largest retailers.
But "manufactured in Europe" does not automatically mean safer. The FDA regulates infant formula sold in the United States regardless of where it is produced, and any product reaching American babies must meet domestic safety standards. Whether the manufacturing process, ingredient sourcing, or handling during distribution contributed to these botulism cases remains unanswered.
Breitbart reported the same core details from the CDC and FDA, including the agency's directive to stop using the formula immediately. The multistate nature of the outbreak, California, Pennsylvania, and Washington, suggests the problem is not tied to a single shipment or regional distribution error.
Several important questions remain open. Federal authorities have not disclosed whether any enforcement action, inspection finding, or specific manufacturing defect has been identified. They have not said whether additional illnesses are under investigation beyond the three confirmed cases. And the exact recall date, described only as "Saturday", has not been pinned to a precise calendar date or timezone.
The absence of a positive lab test for Clostridium botulinum in the formula itself is the biggest outstanding question. If the bacterium is not in the product, how did three babies in three different states develop the same rare illness after consuming the same brand? Investigators will need to answer that before parents, and the market, can move on.
If you have Nara Organics Whole Milk Organic Powdered infant formula in your home, stop using it. Label it, store it, photograph it, and record the lot number. Watch your baby for symptoms. Follow the CDC's guidance to the letter.
Three families trusted a product on Target's shelves to be safe for their newborns. It wasn't. The investigation will sort out the science. But the lesson is older than any lab test: when it comes to what goes into a baby's bottle, "organic" on the label is no substitute for accountability in the supply chain.
